Fibrinolysis and fibrinogenolysis in liver disease

American Journal of Hematology

Volumn 34, Issue 4, 1990, Pages 241-245

  Takahashi, Hoyu ^a   Tatewaki, Wataru ^a   Wada, Ken ^a   Niwano, Hiroe ^a   Shibata, Akira ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

accelerated fibrinolysis; fibrin degradation products; fibrinogen degradation products; hepatitis; liver cirrhosis

Indexed keywords

FIBRIN;

ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGENOLYSIS; FIBRINOLYSIS; HEPATITIS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; PRIORITY JOURNAL;

ANTITHROMBIN III; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HUMAN; LIVER DISEASES; PEPTIDE HYDROLASES; PLASMINOGEN INACTIVATORS; SUPPORT, NON-U.S. GOV'T;

EID: 0025301153     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.2830340402     Document Type: Article

References (34)

1. 2‐plasmin inhibitor levels in liver disease
2. Antithrombin III metabolism in patients with liver disease
3. Abnormal fibrin polymerization in liver disease
4. Acquired dysfibrinogenemia in acute and chronic liver disease
5. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease
6. Acquired dysfibrinogenemia in liver disease
7. Intravascular coagulation in liver disease
8. Intravascular coagulation and the liver
9. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis
10. Fibrinolysis in chronic hepatic insufficiency
11. Studies on a proteolytic enzyme in human plasma. IV. The rate of lysis of plasma clots in normal and diseased individuals, with particular reference to hepatic disease
12. Abnormal plasminogen‐plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: Its cause and consequences
13. Clinical significance of accelerated fibrinolysis in liver disease
14. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: A critical role for tissue plasminogen activator inhibitor
15. Fibrinopeptide A and Bβ15–42 in liver cirrhosis
16. Turnover of human extrinsic (tissue‐type) plasminogen activator in rabbits
17. Renal and hepatic handling of endogenous tissue‐type plasminogen activator (t‐PA) and its inhibitor in man
18. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease
19. An immunoassay for human D‐dimer using monoclonal antibodies
20. Measurement of cross linked fibrin derivatives in plasma: An immunoassay using monoclonal antibodies
21. New enzyme immunoassay of fibrin‐fibrinogen degradation products in plasma using a monoclonal antibody
22. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma
23. A monoclonal antibody‐based enzyme immunoassay for fibrin degradation products in plasma
24. Monoclonal antibodies to crosslinked fibrin degradation products (XL‐FDP). II. Evaluation in a variety of clinical conditions
25. New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies
26. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising Bβ 54‐118) in degradation products of fibrin and of fibrinogen
27. A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A‐containing fragments and not reacting with free fibrinopeptide A
28. Gerinnungs physiologische Schnellmethode zur Bestimmung des Fibrinogens
29. Determination of human throm‐bin‐antithrombin III complex in plasma with an enzyme‐linked immunosorbent assay
30. Thrombin and plasmin generation in patients with liver diséase
31. 2‐plasmin inhibitor
32. Plasminogen activators in alcoholic cirrhosis: Demonstration of increased tissue type and urokinase type activator
33. Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma
34. Plasminogen activator inhibitor type I: Biochemical. biological and clinical aspects